Stocks Vault

[Penny Whisperer]

VLCO update... Great things shining of the horizon...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69138704

[Penny Whisperer]

SBFM .25 Major news out this morning... http://finance.yahoo.com/news/Sunshine-Biopharma-announces-cnw-1078710049.html?x=0&l=1

Sunshine Biopharma announces successful completion of preclinical studies for Adva-27a, the company's lead anti-cancer compound

MONTREAL, Nov. 16, 2011 /CNW Telbec/ - Sunshine Biopharma Inc. (OTCBB: SBFM.OB - News) a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has successfully completed the preclinical studies for Adva-27a, the Company's lead oncology drug candidate. Adva-27a was found to have unique pharmaceutical properties of substantial clinical interest. In summary, the results to date have shown that:

Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells than Etoposide, the drug currently in use.
Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies.
Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar.
Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
Adva-27a's initial indication will be multidrug resistant breast cancer for which there are little or no treatment options.

"We are now ready to move to the next stage in our Adva-27a drug development program," said Dr. Steve N. Slilaty, President and CEO of Sunshine Biopharma. "In this stage we will conduct GMP manufacturing of Adva-27a and then use the material to perform the so-called IND-enabling studies, following which we will file our IND Application and proceed to doing Phase I clinical trials," he added. Dr. Slilaty also stated, "We are delighted to have completed this milestone and are looking forward to the challenges ahead leading to our ultimate goal of improving the quality of life for cancer sufferers."

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contacts

Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
[e-mail]
www.sunshinebiopharma.com

[Cube]

BLSP watch for tmw~bids are deep now

[Penny Whisperer]

TXTM - remember, this one is potentially a multi-day runner... Company conference call on Thursday.... more developments expected.

Short term target by price targeters is .10, so there's still a bit of room to move, here.

[Penny Whisperer]

TXTM .0425 at hod... up 32+%

[Penny Whisperer]

TXTM .042 up 31% in morning trading...

News out this morning... http://finance.yahoo.com/news/Protext-Mobility-Launches-TV-prnews-1189361296.html?x=0&l=1

[Penny Whisperer]

TXTM... .032 Fresh "Unofficial" Alert here.

Seems to be coming off of bottom. Was up 18% yesterday on above average volume and company just announced a conference call with COO and interim-CEO coming up on Thursday to discuss key company plans.

Looks as if this play may be good for more than just one day...perhaps several days. Could easily double from here.

We shall see!

[Penny Whisperer]

VLCO at .047 today... expect mostly upward movement between now and mid December when 10-K comes out.

[Penny Whisperer]

CLRN closed today at .0064... originally alerted here and on twitter at .0051. Currently sitting at a potential 25% gain.

[Penny Whisperer]

CLRN .0051 has provided 2 100%+ opportunities since yesterday afternoon.

[Penny Whisperer]

Long Term buy and hold play: VLCO!

DD here... http://investorshub.advfn.com/boards/read_msg.aspx?message_id=68836535

10-K expected by mid December. Numbers are expected to be phenomenal.

Audited financials.

Already extremely undervalued here. Won't be long and I think that .043 will be a thing of the distant past.

[Penny Whisperer]

CLRN alerted this morning at .0053 reaches a high of .01 for nearly 100% gains today.

[Penny Whisperer]

ACTN alerted on Tuesday at .50 closes at the high of the day of 2.10 for more than a 300% gain.